Wilfried Reichardt, Tabea Gewalt, Philipp Hafner, Steffen J Keller, Xun Chen, Asma Alrawashdeh, Yayu Li, Solène Besson, Stefan Fichtner-Feigl, Dominik von Elverfeldt, Huda Jumaa, Dietrich A Ruess
{"title":"基于荧光磁共振成像的胰腺癌纵向免疫微环境监测。","authors":"Wilfried Reichardt, Tabea Gewalt, Philipp Hafner, Steffen J Keller, Xun Chen, Asma Alrawashdeh, Yayu Li, Solène Besson, Stefan Fichtner-Feigl, Dominik von Elverfeldt, Huda Jumaa, Dietrich A Ruess","doi":"10.1002/jmri.29589","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Pancreatic cancer has a poor prognosis. Targeting Kirsten Rat Sarcoma (KRAS) mutation and its related pathways may enhance immunotherapy efficacy. While in vivo monitoring of therapeutic response and immune cell migration remains challenging, Fluorine-19 MRI (<sup>19</sup>F MRI) may allow noninvasive longitudinal imaging of immune cells.</p><p><strong>Purpose: </strong>Evaluating the potential of <sup>19</sup>F MRI for monitoring changes in the tumor immune microenvironment, in response to combined SHP2/MEK inhibition.</p><p><strong>Study type: </strong>Pre-clinical animal study.</p><p><strong>Animal model: </strong>Murine genetically engineered pancreatic cancer model (N = 20, both sexes).</p><p><strong>Field strength/sequence: </strong>9.4-T, two-dimensional multi-slice Rapid Acquisition with Relaxation Enhancement sequence. Intravenous injection of <sup>19</sup>F-perfluorocarbon (PFC) nanoparticles.</p><p><strong>Assessment: </strong>Upon tumor detection by conventional <sup>1</sup>H MRI screening, <sup>19</sup>F MRI was performed in mice 24 hours after PFC nanoparticle administration. Animals were randomly assigned to four treatment groups: allosteric Src-homology-2-containing protein tyrosine phosphatase 2 (SHP2) inhibitor SHP099, the mitogen-activated extracellular signal-regulated kinase 1/2 (MEK1/2) inhibitor Trametinib, the combination of both, or a vehicle control (4 to 6 mice each group), administered every other day per oral gavage. <sup>1</sup>H and <sup>19</sup>F MRI was repeated 7 days and 14 days later. Pancreatic immune cell infiltrates were analyzed by flow cytometry and multiplex immunohistofluorescence (mIHF) upon sacrifice.</p><p><strong>Statistical tests: </strong>Independent t-tests and one-way analysis of variance.</p><p><strong>Results: </strong><sup>19</sup>F MRI revealed continuous decrease of PFC-signals in tumors from vehicle controls (100%, 80%, and 74% on days 0, 7, and 14, respectively), contrasting with stable or increasing signals under KRAS-pathway-directed treatment. MEK inhibition showed 100%, 152%, and 84% and dual SHP2/MEK1/2 inhibition demonstrated signals of 100%, 134%, and 100% on days 0, 7, 14, respectively. mIHF analyses indicated CD11b<sup>+</sup> macrophages/monocytes as primary contributors to the observed <sup>19</sup>F MRI signal differences.</p><p><strong>Data conclusion: </strong><sup>19</sup>F MRI might provide non-invasive longitudinal estimates for abundance and spatial distribution of CD11b<sup>+</sup> macrophages/monocytes in pancreatic cancer.</p><p><strong>Evidence level: </strong>1 TECHNICAL EFFICACY: Stage 2.</p>","PeriodicalId":16140,"journal":{"name":"Journal of Magnetic Resonance Imaging","volume":" ","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"<sup>19</sup>Fluorine-MRI Based Longitudinal Immuno-Microenvironment-Monitoring for Pancreatic Cancer.\",\"authors\":\"Wilfried Reichardt, Tabea Gewalt, Philipp Hafner, Steffen J Keller, Xun Chen, Asma Alrawashdeh, Yayu Li, Solène Besson, Stefan Fichtner-Feigl, Dominik von Elverfeldt, Huda Jumaa, Dietrich A Ruess\",\"doi\":\"10.1002/jmri.29589\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Pancreatic cancer has a poor prognosis. Targeting Kirsten Rat Sarcoma (KRAS) mutation and its related pathways may enhance immunotherapy efficacy. While in vivo monitoring of therapeutic response and immune cell migration remains challenging, Fluorine-19 MRI (<sup>19</sup>F MRI) may allow noninvasive longitudinal imaging of immune cells.</p><p><strong>Purpose: </strong>Evaluating the potential of <sup>19</sup>F MRI for monitoring changes in the tumor immune microenvironment, in response to combined SHP2/MEK inhibition.</p><p><strong>Study type: </strong>Pre-clinical animal study.</p><p><strong>Animal model: </strong>Murine genetically engineered pancreatic cancer model (N = 20, both sexes).</p><p><strong>Field strength/sequence: </strong>9.4-T, two-dimensional multi-slice Rapid Acquisition with Relaxation Enhancement sequence. Intravenous injection of <sup>19</sup>F-perfluorocarbon (PFC) nanoparticles.</p><p><strong>Assessment: </strong>Upon tumor detection by conventional <sup>1</sup>H MRI screening, <sup>19</sup>F MRI was performed in mice 24 hours after PFC nanoparticle administration. Animals were randomly assigned to four treatment groups: allosteric Src-homology-2-containing protein tyrosine phosphatase 2 (SHP2) inhibitor SHP099, the mitogen-activated extracellular signal-regulated kinase 1/2 (MEK1/2) inhibitor Trametinib, the combination of both, or a vehicle control (4 to 6 mice each group), administered every other day per oral gavage. <sup>1</sup>H and <sup>19</sup>F MRI was repeated 7 days and 14 days later. Pancreatic immune cell infiltrates were analyzed by flow cytometry and multiplex immunohistofluorescence (mIHF) upon sacrifice.</p><p><strong>Statistical tests: </strong>Independent t-tests and one-way analysis of variance.</p><p><strong>Results: </strong><sup>19</sup>F MRI revealed continuous decrease of PFC-signals in tumors from vehicle controls (100%, 80%, and 74% on days 0, 7, and 14, respectively), contrasting with stable or increasing signals under KRAS-pathway-directed treatment. MEK inhibition showed 100%, 152%, and 84% and dual SHP2/MEK1/2 inhibition demonstrated signals of 100%, 134%, and 100% on days 0, 7, 14, respectively. mIHF analyses indicated CD11b<sup>+</sup> macrophages/monocytes as primary contributors to the observed <sup>19</sup>F MRI signal differences.</p><p><strong>Data conclusion: </strong><sup>19</sup>F MRI might provide non-invasive longitudinal estimates for abundance and spatial distribution of CD11b<sup>+</sup> macrophages/monocytes in pancreatic cancer.</p><p><strong>Evidence level: </strong>1 TECHNICAL EFFICACY: Stage 2.</p>\",\"PeriodicalId\":16140,\"journal\":{\"name\":\"Journal of Magnetic Resonance Imaging\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2024-08-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Magnetic Resonance Imaging\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/jmri.29589\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Magnetic Resonance Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/jmri.29589","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
19Fluorine-MRI Based Longitudinal Immuno-Microenvironment-Monitoring for Pancreatic Cancer.
Background: Pancreatic cancer has a poor prognosis. Targeting Kirsten Rat Sarcoma (KRAS) mutation and its related pathways may enhance immunotherapy efficacy. While in vivo monitoring of therapeutic response and immune cell migration remains challenging, Fluorine-19 MRI (19F MRI) may allow noninvasive longitudinal imaging of immune cells.
Purpose: Evaluating the potential of 19F MRI for monitoring changes in the tumor immune microenvironment, in response to combined SHP2/MEK inhibition.
Study type: Pre-clinical animal study.
Animal model: Murine genetically engineered pancreatic cancer model (N = 20, both sexes).
Field strength/sequence: 9.4-T, two-dimensional multi-slice Rapid Acquisition with Relaxation Enhancement sequence. Intravenous injection of 19F-perfluorocarbon (PFC) nanoparticles.
Assessment: Upon tumor detection by conventional 1H MRI screening, 19F MRI was performed in mice 24 hours after PFC nanoparticle administration. Animals were randomly assigned to four treatment groups: allosteric Src-homology-2-containing protein tyrosine phosphatase 2 (SHP2) inhibitor SHP099, the mitogen-activated extracellular signal-regulated kinase 1/2 (MEK1/2) inhibitor Trametinib, the combination of both, or a vehicle control (4 to 6 mice each group), administered every other day per oral gavage. 1H and 19F MRI was repeated 7 days and 14 days later. Pancreatic immune cell infiltrates were analyzed by flow cytometry and multiplex immunohistofluorescence (mIHF) upon sacrifice.
Statistical tests: Independent t-tests and one-way analysis of variance.
Results: 19F MRI revealed continuous decrease of PFC-signals in tumors from vehicle controls (100%, 80%, and 74% on days 0, 7, and 14, respectively), contrasting with stable or increasing signals under KRAS-pathway-directed treatment. MEK inhibition showed 100%, 152%, and 84% and dual SHP2/MEK1/2 inhibition demonstrated signals of 100%, 134%, and 100% on days 0, 7, 14, respectively. mIHF analyses indicated CD11b+ macrophages/monocytes as primary contributors to the observed 19F MRI signal differences.
Data conclusion: 19F MRI might provide non-invasive longitudinal estimates for abundance and spatial distribution of CD11b+ macrophages/monocytes in pancreatic cancer.
期刊介绍：
The Journal of Magnetic Resonance Imaging (JMRI) is an international journal devoted to the timely publication of basic and clinical research, educational and review articles, and other information related to the diagnostic applications of magnetic resonance.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
